MPs to explore Merck’s decision to abandon expansion of UK operations
The Science, Innovation and Technology Committee will hold a one-off evidence session to explore the decision by Merck (known as MSD in Europe) to halt its £1bn UK expansion, and what it means for investment in the UK’s life sciences sector.
Meeting details
At 2:45pm: Oral evidence
Work
Life sciences investment (Non-inquiry session)
VP Managing Director UK and Ireland at MSD
Chief Executive at ABPI (The Association of the British Pharmaceutical Industry)
UK President at AstraZeneca
At 3:30pm: Oral evidence
Work
Life sciences investment (Non-inquiry session)
Minister for Science, Research and Innovation at DSIT
Director at Office for Life Sciences
Parliamentary Under-Secretary of State at Department of Health and Social Care (DHSC)
During the session, the cross-party committee will question representatives of the pharmaceutical industry and the government.
Witnesses:
- Ben Lucas, Vice President Managing Director, UK& Ireland, MSD
- Richard Torbett, Chief Executive, ABPI
- Tom Keith-Roach, UK President, AstraZeneca
- Lord (Patrick) Vallance, Minister for Science, Research and Innovation, Department for Science, Innovation and Technology
- Rosalind Campion, Director, Office for Life Sciences (OLS)
- Dr Zubir Ahmed MP, Parliamentary Under-Secretary of State at the Department of Health and Social Care